These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25795166)

  • 21. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
    Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
    J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance.
    Steegen K; Demecheleer E; De Cabooter N; Nges D; Temmerman M; Ndumbe P; Mandaliya K; Plum J; Verhofstede C
    J Virol Methods; 2006 May; 133(2):137-45. PubMed ID: 16375980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance.
    Van den Eede P; Van Wesenbeeck L; Verlinden Y; Feyaerts M; Smits V; Verheyen A; Vanhooren L; Deloof A; Villacian J; Pattery T
    Methods Mol Biol; 2013; 1030():37-55. PubMed ID: 23821259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular diversity of HIV-1 and surveillance of transmitted drug resistance variants among treatment Naïve patients, 5 years after active introduction of HAART in Kuala Lumpur, Malaysia.
    Ong LY; Razak SN; Lee YM; Sri La Sri Ponnampalavanar S; Syed Omar SF; Azwa RI; Tee KK; Kamarulzaman A
    J Med Virol; 2014 Jan; 86(1):38-44. PubMed ID: 24127302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [HIV-1 drug-resistance profiles of treated AIDS patients in Liaoning: genetic characteristics and prevalence].
    Wu SH; Lu CM; Jiang FX; Ma N; E S; Pan S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1273-6. PubMed ID: 20193313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a new comprehensive HIV-1 genotypic drug resistance assay for all commercially available reverse transcriptase, protease and integrase inhibitors in patients infected with group M HIV-1 strains.
    Chrysostomou AC; Topcu C; Stylianou DC; Hezka J; Kostrikis LG
    Infect Genet Evol; 2020 Jul; 81():104243. PubMed ID: 32061896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
    Narciso P; Lazzarin A
    Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.
    Walter H; Schmidt B; Korn K; Vandamme AM; Harrer T; Uberla K
    J Clin Virol; 1999 Jun; 13(1-2):71-80. PubMed ID: 10405894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays.
    Gonzalez R; Masquelier B; Fleury H; Lacroix B; Troesch A; Vernet G; Telles JN
    J Clin Microbiol; 2004 Jul; 42(7):2907-12. PubMed ID: 15243037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recombinant virus assay using full-length envelope sequences to detect changes in HIV-1 co-receptor usage.
    Dittmar MT; Eichler S; Reinberger S; Henning L; Kräusslich HG
    Virus Genes; 2001 Dec; 23(3):281-90. PubMed ID: 11778696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors.
    Sá-Ferreira JA; Brindeiro PA; Chequer-Fernandez S; Tanuri A; Morgado MG
    Transfusion; 2007 Jan; 47(1):97-102. PubMed ID: 17207236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic susceptibility to antiretrovirals among clades C, F, and B/F recombinant antiretroviral-naive HIV type 1 strains.
    Sucupira MC; Munerato P; Silveira J; Santos AF; Janini LM; Soares MA; Diaz RS
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):880-6. PubMed ID: 23398474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.